Additional Information

Description

Wegovy (Semaglutide) 1.7 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management in adults with obesity or overweight conditions associated with weight-related comorbidities. It works by mimicking the natural GLP-1 hormone, which regulates appetite, reduces food intake, slows gastric emptying, and enhances insulin sensitivity, leading to significant weight loss over time.

Each prefilled injection pen delivers 1.7 mg of semaglutide in a single dose for subcutaneous administration. The recommended starting dose is 0.25 mg once weekly for four weeks to allow the body to adjust to the medication. After the initial period, the dosage is gradually increased based on patient tolerance and treatment goals, with a maximum maintenance dose of 2.4 mg weekly.

Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue. More serious adverse effects may include pancreatitis, gallbladder disease, and worsening of diabetic retinopathy. Patients should be monitored regularly for metabolic response, gastrointestinal tolerance, and signs of serious complications.